Inflammation and Joint Tissue Interactions in OA: Implications for Potential Therapeutic Approaches by Rainbow, Roshni et al.
Hindawi Publishing Corporation
Arthritis
Volume 2012, Article ID 741582, 8 pages
doi:10.1155/2012/741582
Review Article
Inﬂammation and Joint Tissue Interactions in OA:
Implications for Potential Therapeutic Approaches
Roshni Rainbow,1 WeipingRen,2 and Li Zeng1,3
1Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, MA 02111, USA
2Department of Biomedical Engineering, Wayne State University, Detroit, MI 48201, USA
3Department of Orthopaedic Surgery, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
Correspondence should be addressed to Li Zeng, li.zeng@tufts.edu
Received 12 January 2012; Revised 4 April 2012; Accepted 26 April 2012
Academic Editor: Changhai Ding
Copyright © 2012 Roshni Rainbow et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
It is increasingly recognized that the pathogenesis of cartilage degradation in osteoarthritis (OA) is multifactorial and involves
the interactions between cartilage and its surrounding tissues. These interactions regulate proinﬂammatory cytokine-mediated
cartilage destruction, contributing to OA progression as well as cartilage repair. This review explores the pathogenesis of OA in the
contextofthemultipletissuetypesinthejointanddiscussestheimplicationsofsuchcomplextissueinteractioninthedevelopment
of anti-inﬂammatory therapeutics for the treatment of OA.
1.Introduction
Situated between bone surfaces, articular cartilage serves as a
protective cushion for severe mechanical loading. Extended
wear of this tissue can lead to osteoarthritis (OA), a disease
estimated to aﬀect over 67 million North Americans by
the year 2030 [1]. It has been well studied that OA is a
complex, multifactorial inﬂammatory disease of the whole
joint, whose development and progression is signiﬁcantly
mediated by interactions between the joint cartilage and
its surrounding tissues. Notably, proinﬂammatory cytokine-
mediated interactions between tissue types contribute to
the pathogenesis of OA. The current standard of care
for OA involves drug therapies that help to manage and
alleviate disease symptoms, with a variety of treatments
targeting the inﬂammatory mediators present during OA
pathogenesis. Appropriately, the following review explores
OA in the context of how tissues in the joint interact to
contribute to inﬂammation-associated cartilage degradation
and the implications of these complex interactions in the
development of anti-inﬂammatory treatments that targetthe
whole joint.
2. ProinﬂammatoryCytokinesMediate
Cartilage Degradation
While the biological onset of OA is not clearly understood,
evidence suggests that the progression of cartilage degrada-
tion is mediated largely by proinﬂammatory cytokines, most
notably interleukin 1-beta (IL-1β) and tumor necrosis factor
alpha (TNFα)[ 2, 3]. These cytokines contribute to tissue
destruction by disrupting the balance of the catabolic and
anabolic activities of chondrocytes, the major cell type of
cartilage tissue. Much of the activities of proinﬂammatory
cytokines are mediated by the activation of transcrip-
tion factor nuclear factor kappa B (NFκB), which further
leads to the induction of inducible nitric oxide synthase
(iNOS), cyclooxygenase 2 (COX-2), nitric oxide (NO), and
prostaglandin E2 (PGE-2) [3]. As a result, OA chondrocytes
have reduced expression of extracellular matrix components,
such as type II collagen (Col II) and aggrecan, as well as
increased production of proteolytic enzymes, such as matrix
metalloproteinases (MMPs) and peptidases of a disintegrin
and metalloproteinase with thrombospondin motifs family
(ADAMTSs) [2–5].2 Arthritis
3. Effect of Joint Tissues in the Pathogenesis of
CartilageDestruction in OA
While OA has been historically deﬁned as “wear and tear”
of articular cartilage, it is increasingly recognized that associ-
ated inﬂammation and subsequent tissue degradation is the
result of multiple joint tissue interactions with cartilage. In
general, tissues in the vicinity of the joint cartilage consist of
subchondral bone, synovium, muscle, tendon, ligament, and
fat pad (Figure 1). These tissues regulate proinﬂammatory
cytokine-mediated cartilage destruction, contributing to OA
pathogenesis as well as cartilage repair. The following section
highlights the important contributions and interactions of
the various joint tissues during OA progression.
3.1. Bone. During the progression of OA, subchondral bone
undergoes signiﬁcant morphological changes that include
increased bone volume and remodeling, tissue sclerosis,
and the formation of osteophytes at the joint margins [6].
These changes correlate with increased signal intensities in
MRI images from subchondral bone during OA, which are
termed bone marrow lesions (BMLs) [7–9]. Longitudinal
studies indicate that alterations in the subchondral bone
take place before any detectable radiographic changes in
articular cartilage, thereby suggesting that the underlying
bone tissue may regulate the initiation of cartilage loss [10].
Correspondingly,duringOA,thereisanincreasedexpression
of inﬂammatory cytokines in the subchondral bone [11–
13].Whilethepermeabilityofsuchbone-derivedfactorsinto
cartilage tissue is limited in the healthy joint, pathogenesis of
OA contributes to cracking within the articular and calciﬁed
cartilage zones and promotes diﬀusion of inﬂammatory
cytokines from the bone into the cartilage through ﬁssures
at the osteochondral junction [11]. Indeed, direct signaling
between cartilage and bone cells was demonstrated in
coculture experiments where OA-derived osteoblasts down-
regulatedexpression ofproteoglycans andupregulatedMMP
production in chondrocytes, suggesting an adverse eﬀect of
OA subchondral bone toward the overlying cartilage [14–
16]. In addition to facilitating diﬀusion of secreted factors,
crevices at the osteochondral junction in late stage OA have
also been shown to facilitate the movement of migratory
cell clusters that possess strong chondrogenic potential and
which may play an important role in cartilage repair [17].
3.2. Muscle. Muscle is long known to provide biomechanical
stimulitocartilageasmuscle-generatedmovementpromotes
nutrientdistributionandmaintainshomeostasisofchondro-
cytes [18, 19]. Recently, it was established that muscle tissue
also secretes myokines that have anti-inﬂammatory activities
[20]. Coculturing chondrocytes with skeletal muscle cells or
muscle cell conditioned medium led to increased cartilage
matrix production and increased resistance to proinﬂamma-
tory cytokine IL-1β-a n dT N F α-induced cartilage damage
[21,22].Theseresultssuggestthatmusclecellsregulatecarti-
lage homeostasis not only through biomechanical forces, but
also through biochemical signals. In fact, quadricep muscle
weakness, which reduces both biomechanical and biochem-
ical output from muscle, precedes pain and disability of the
joint during OA progression, thereby suggesting a possible
causative relationship between muscle and cartilage [23].
3.3. Adipose Tissue. It is known that obesity is a major risk
factor for the development and progression of OA [24, 25].
While increased weight certainly would contribute to OA
through increased mechanical pressure, careful studies indi-
cate that OA incidence in nonweight bearing joints is also
higher in obese patients [24, 26], suggesting that adipose
tissue has a biochemical output that aﬀects joint cartilage
systemically. Fat pads, located within the joint capsules,
may also exert a more local eﬀect on cartilage homeostasis,
and the infrapatellar fat pad (IFP) was found to increase
in size with aging in OA patients [27]. The IFP secretes a
substantial amount of adipokines, particularly adiponectin,
leptin,andresistin,allwhichareelevatedinthesynovialﬂuid
of joints with advanced OA [28–32]. Although other tissues
also secrete these factors, the IFP is a major contributor
to adipokine presence in the joint. In particular, leptin is
considered to be a proinﬂammatory cytokine and causes
catabolic changes in chondrocytes, inducing the expression
levels of cartilage degrading enzymes MMPs and ADAMTSs
and showing a synergistic role with IL-1β to cause cartilage
destruction [33–36]. It has been demonstrated that leptin
mutant mice, although obese, do not develop OA, thereby
strongly suggesting that leptin is required for the develop-
ment of arthritis in obese mice [37, 38]. Consistent with
this study, mutations in the leptin gene are found to be
associated with susceptibility to knee OA [39]. However,
compared with leptin, the eﬀect of adiponectin in OA still
remains controversial. While some reports indicated that
adiponectin inhibited IL-1β-induced MMP13 induction in
primary chondrocytes [40], others showed that it enhanced
the production of nitric oxide (NO) and the expression of
MMPs in OA chondrocytes [41–43]. It has been shown that
serum adiponectin level was signiﬁcantly lower in OA mice
and reversely correlated with OA severity in humans [43,
44]. In contrast, expression levels of adiponectin receptors
(AdipoR) were elevated in the articular cartilage of OA
patients [41]. Other adipokines such as resistin and visfatin
have also been shown to be proinﬂammatory and play a
role in enhancing cartilage degradation by inducing IL-1β
expression and downregulating proteoglycan synthesis [45].
Taken together, articular cartilage is likely aﬀected by the
combinatorial activities of all these adipokines, and it has
been found that it is the ratio of adiponectin to leptin in the
synovial ﬂuid that predicts pain in knee OA patients [46].
3.4. Synovium. In the synovial joint, articular cartilage is
bathed in synovial ﬂuid within the joint cavity [47]. This
cavity is lined with two types of cells, synoviocytes that
are ﬁbroblast-like cells and macrophages [48]. Synovio-
cytes secrete lubricin and hyaluronan, two key components
involved in the lubrication function of synovial ﬂuid [49].
Synovitis, common in both early- and late-stage OA, is a
condition that occurs when the synovium becomes inﬂictedArthritis 3
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with inﬂammation [50]. This condition is marked by dra-
matically increased secretion of proinﬂammatory cytokines
andproteolyticenzymesfromsynovium-liningcells[51–55].
Proinﬂammatory cytokines, most notably IL-1β,I L - 6 ,a n d
TNFα,arethoughttomediate the progressionandpain asso-
ciated with this disease [50, 56]. Adipokines, such as resistin
[45], are also increasingly expressed by the synovium during
OA, as is osteopontin [57], a cytokine whose increased
expression levels have been correlated with disease severity.
Furthermore, ex vivo coculturing of joint capsule tissue with
damaged cartilage has demonstrated the contribution of
the synovium to shifting chondrocyte metabolism towards
matrix degradation [58–60]. In addition to providing signal-
ing molecules that regulate articular cartilage gene expres-
sion,synoviocytesthemselvescandiﬀerentiateintochondro-
cytes. Recently, a population of CD73-positive cells were
identiﬁedinthesynovium,whichpossessmesenchymalstem
cell-likecharacteristics,suchasslow-cyclingandtheabilityto
diﬀerentiate into multiple lineages, including chondrogenic
and osteogenic, in vitro [61, 62]. Thus, these cells may serve
as an attractive cell source for cartilage regeneration and
repair [63]. Indeed, synoviocytes were proposed to con-
tribute to the layer of ﬁbrous tissue, called the “pannus-like”
layer, which is frequently found to be overlying the articular
cartilage in OA joints [64, 65] .H o w e v e r ,ar e c e n ts t u d y
indicates that synoviocytes from OA patients do not have the
ability to colonize adjacent cartilage[66],suggestingthat this
tissue may not be derived directly from synoviocytes. In the
same study, it was shown that synoviocytes from rheumatoid
arthritis (RA) patients, on the other hand, had the ability
to attach to adjacent cartilage and to even spread to other
joints of the body [66]. This indicates a distinct diﬀerence
between synoviocytes of OA and RA patients, suggesting that
the joint capsule is permeable enough to allow not only ﬂuid
or secreted factors, but also cells to pass through.
4. Therapeutic Approaches for OA
The current standard of care for OA involves the use of
drugs that help to manage and alleviate disease symptoms.
Common early-stage OA treatment options include the
use of analgesics and nonsteroidal anti-inﬂammatory drugs
(NSAIDs) [67, 68]. While both analgesics and NSAIDs are
utilized to alleviate pain symptoms, NSAIDs speciﬁcally act
by targeting the inﬂammation associated with OA through
the inhibition of COX [67]. The COX enzyme mediates
the synthesis of prostaglandins (PG), biomolecules involved
in inﬂammation, and two classes of COX inhibitors exist,
COX-1 and COX-2, with COX-2 inhibitors being developed
to avoid the gastrointestinal side eﬀects associated with the
long-term use of COX-1 inhibitors. Both analgesics and
NSAIDs can be administered orally or topically; however,
the latter has proven to be a less eﬀective [69, 70]. Despite
their popularity, NSAIDs do not slow down the progression
of OA through any disease modiﬁcation and the eﬃcacy of
treatment as compared to placebo therapy is often times
minimal[71].Additionally,thereiscontroversyastowhether
NSAIDs actually inhibit cartilage degradation or worsen the
conditions of OA by providing an analgesic eﬀect or adverse
side eﬀects [68].
An alternative treatment option to NSAIDs includes the
use of hyaluronic acid (HA) and corticosteroids [72]. While4 Arthritis
endogenous HA provides adequate viscoelastic and lubricat-
ing properties to maintain joint homeostasis in a healthy
joint, during OA, the properties of HA are diminished and
contribute to further cartilage destruction [73, 74]. Intra-
articular injection of HA has been shown to inhibit cartilage
degradation, induce matrix synthesis, reduce pain symp-
toms, and downregulate the expression of proinﬂammatory
mediators [74, 75]. It is important to note that the eﬀect
of HA is dependent on its molecular weight (MW), as only
cross-linked or higher MW HA is eﬀective in mitigating
inﬂammation, while lower MW HA or HA fragments are
proinﬂammatory [76, 77]. Indeed, a recent report of a
clinical trial using HA therapy indicated that intermediate
MW HA was more superior as compared to low MW
HA in alleviating knee OA symptoms [78]. Similar to HA,
intra-articular administration of low dose corticosteroids
has shown to reduce both the expression of proinﬂam-
matory mediators and the permeability in the inﬂamed
area by lessening vascular dilation [79], as well as decrease
inﬂammation and swelling in OA joints, thereby managing
pain and enhancing joint mobility [80]. For both HA and
corticosteroid treatment, rates of adverse side eﬀects are low;
however, it is worth noting that corticosteroids, particularly
a tah i g h e rl e v e l ,m a yh a v ead a m a g i n ge ﬀect toward bone
formation [69, 81]. As OA is a disease of the whole joint, it
is especially important to consider the eﬀect of these drugs
on all cell types in the joint. Furthermore, success with such
therapies has been shown to be beneﬁcial only the ﬁrst few
weeks after intra-articular injection. As a result, repeated
and invasive injection treatments are needed for maintaining
long-term eﬃcacy [67].
Antibiotics, such as doxycycline, have also been explored
for their role as disease modifying drugs in the treatment
of OA. Preclinical trials using a guinea pig OA model and
magnetic resonance imaging (MRI) suggest the protective
role of this drug in lessening cartilage volume loss and
inhibiting MMP activity [82]. However, this treatment
option is controversial as the deﬁnitive role of doxycycline
during OA treatment is not well understood. For example,
anOArabbitmodelhasdemonstratedthatwhiledoxycycline
treatment was inconclusive in deﬁnite treatment of OA,
cartilaginous changes observed in these studies suggest a
potential role of doxycycline in disease modiﬁcation [83].
Humantrialsexploringdoxycyclineasatreatmentoptionfor
kneejointOAsuggestthatwhilethisdrugmayslowdownthe
rate of joint space narrowing, there lacks deﬁnitive evidence
of symptomatic improvement [84]. Furthermore, in vitro
studies on the eﬀect of doxycycline on cartilage degradation
have shown that while this antibiotic has an inhibitory role
on aggrecanase expression, there is no indication of pro-
teoglycan synthesis or loss under inﬂammatory conditions
[85].
As proinﬂammatory cytokines play a signiﬁcant role in
mediating cartilage degradation and OA-associated inﬂam-
mation, the inhibition of such factors, particularly IL-1β
and TNFα, could be a viable therapy for slowing down the
progressionofOA.Inaccordance,newclassesofdrugs,called
disease modiﬁcation OA drugs (DMOADs), have become
increasingly promising therapies [71, 86]. While still an
emerging therapy, DMOADs aim to provide structural and
metabolic changes to the inﬂammatory joint environment,
with hopes to slow down the progression of OA and possibly
provide healing to already damaged cartilage. Drugs, such as
inhibitors of iNOS and avocado-soyabean unsaponiﬁables,
are currently being explored in trial for their role in reducing
OA-associated inﬂammation. While iNOS inhibitors curb
the activation of MMPs, avocado-soyabean unsaponiﬁables
have an anti-inﬂammatory eﬀect on chondrocytes and in-
hibit the breakdown of cartilage matrix and are currently
being explored in Phase III clinical trails [71]. Other
drugs, such as statins, commonly prescribed for cholesterol
reduction, have shown promising results in vitro to reduce
MMP-3 production in IL-1β stimulated chondrocytes
[87].
While DMOADs are being explored as an alternative to
current treatment options, success of these therapies will
require further study. For example, IL-1β receptor antag-
onists have been shown to have a promising eﬀect in the
inhibition of structural changes occurring during OA in rab-
bit, canine, and horse models [2], but remain inconclusive
in humans [68]. Caspase-1 inhibitors have been shown to
reduce joint damage mediated by IL-1 in murine models;
however, adverse side eﬀects in humans have resulted in
clinical trials being put on hold [67].
As highlighted in this paper, multiple tissues contribute
to the inﬂammatory microenvironment and subsequent
cartilage degradation during OA pathogenesis, and these
tissue interactions may provide an attractive disease mod-
iﬁcation pathway with respect to therapeutic treatment.
For example, subchondral bone, with its contributions to
cartilage degradation during OA, is one tissue type that is
currently being explored as a disease modiﬁcation target
for three DMOADs in clinical trial. Currently in Phase III
clinical trial [71], calcitonin, a hormone regulating calcium
homeostasis, has been shown to inhibit MMP activity and
subsequent cartilage degradation [88]. Additionally, bone
morphogenetic protein 7 (BMP-7), a potent bone-inducing
agent, has been shown to stimulate proteoglycan, collagen,
and HA synthesis in cartilage [89, 90], while vitamin D has
been shown to reduce the progression of osteoarthritis [91].
Both BMP-7 and vitamin D are in Phase II trials [71].
Because OA joints have decreased mineral content and
increased bone turnover, bisphosphonates have been also
explored as potential DMOADs with respect to targeting
the subchondral bone during OA progression [92]. These
molecules have been shown to inhibit bone resorption and
reduce the synthesis of inﬂammatory mediators as well as
increase cartilage volume in canine OA models [93, 94]. The
combined use of bisphosphonates with NSAIDs as a therapy
for early OA has shown to preserve bone mass, decrease
osteophyte formation, and increase OA severity [95].
Modiﬁcation of the contributions of the synovial mem-
brane during OA has also been explored as a treatment
option through the use of chondroitin sulfate, which has
been shown to reduce signs of synovitis and inﬂammation
in the joint space [96]. Likewise, contributions of adipose
tissuetoOAarealsobeingexploredasapotentialtherapeutic
target.Arthritis 5
5. Advancements in Drug Delivery
When present, OA often aﬀects multiple joints, and as a
result, a drug therapy that can target a variety of joint tissues
in the body is highly desirable. For example, as discussed
above, many NSAIDS and COX inhibitors can be adminis-
teredorallytohaveasystemicaﬀecttothewholebody.While
systemic delivery allows the treatment of multiple aﬀected
joints, localized drug delivery to the joint microenvironment
is an optimal therapeutic approach when the number of
joints aﬀected is limited. Here, oral or injection delivery may
notprovideadequatedrugconcentrationsorreleasekinetics.
Furthermore, high systemic concentrations that are required
to achieve the appropriate therapeutic concentrations within
the joint space may result in adverse side eﬀects [97–99]. In
the intra-articular space, for example, synovial membrane
permeability can result in increased diﬀusion of drugs out
of the joint space, and together with shorter drug half-
life, can result in shorter joint residence times. Here, while
injections are a possible method to increase local delivery to
the joint space, they are quite invasive and may be increased
in frequency to achieve eﬃcacy. To circumvent such issues,
there is interest in developing localizable methods that can
achieve sustained, pro-longed delivery, particularly for the
intra-articular joint space [100]. Acting as a depot for the
therapeutic drug, liposome- and polymeric-based systems
have been widely explored in vivo for the controlled delivery
of OA treatment drugs [101]. Here, the therapeutic drug is
entrapped within a liposome or a biodegradable polymeric
matrix, allowing for prolonged bioavailability and increasing
drug residence time in the joint cavity. The stability and
the degradation of the lipids and polymers composing
such structures allow for control over the timing and
dosage of delivery [101, 102]. While such methods are a
promising delivery strategy for intra-articular delivery, only
one clinical therapy exists to date for OA that combines
the use of intra-articular injections with liposomes con-
taining dexamethasone-21-palmitate [98]. With respect to
polymeric-based intra-articular drug treatments, albumin
microspheres have been explored for delivery of NSAIDS
including diclofenac sodium [103] and COX-2 inhibitor
celecoxib [104]. Likewise, poly(lactic acid) and poly(lactic-
coglycolic acid) (PLA/PLGA) have been explored as delivery
matrices for NSAIDs, such as betamethasone sodium phos-
phate [105], corticosteroids, such as methylprednisolone
[106], and DMOADs such as BMP-7 [107].
6. Conclusion
OA is recognized as a multifactorial inﬂammatory disease of
the whole joint, with a complex pathomechanism involving
interactions between the multiple joint tissues. Furthermore,
the development of OA is largely mediated by proinﬂam-
matory cytokines and their subsequent contributions to car-
tilage degradation. Current therapies manage OA largely by
alleviatingsymptomsandpain;however,drugsthatintercede
the inﬂammatory OA pathway are actively being explored as
therapeutic options. Such drugs may be delivered systemi-
cally, which may be particularly relevant for the treatment of
multiple joints within the body at once, or may be delivered
locally to a single joint space using intra-articular injections
or other localizable drug delivery methods. Regardless of the
delivery modality, a varying collection of approaches to OA
will likely be required to exploit the complex interactions
between joint tissues.
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